Success Metrics

Clinical Success Rate
100.0%

Based on 3 completed trials

Completion Rate
100%(3/3)
Active Trials
0(0%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_4
2
50%
Ph phase_3
1
25%

Phase Distribution

0

Early Stage

0

Mid Stage

3

Late Stage

Phase Distribution3 total trials
Phase 3Large-scale testing
1(33.3%)
Phase 4Post-market surveillance
2(66.7%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

100.0%

3 of 3 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

4

all time

Status Distribution
Completed(3)
Other(1)

Detailed Status

Completed3
unknown1

Development Timeline

Analytics

Development Status

Total Trials
4
Active
0
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Phase 31 (33.3%)
Phase 42 (66.7%)

Trials by Status

completed375%
unknown125%

Recent Activity

0 active trials
Showing 4 of 4
completedphase_4

Safety and Efficacy of Sofosbuvir-Based Regimens in the Treatment of Egyptian Patients With Hepatitis C Infection

NCT02992457
unknownphase_3

PK of SOF/LED in HCV - Infected Adolescents With Haematological Disorders

NCT04353986
completedphase_4

Sofosbuvir/Ledipasvir and Nitazoxanide for Treatment of COVID-19

NCT04498936
completed

eGFR Evolution in HCV Patients Receiving SOF-based or SOF-free DAAs

NCT04047680

Clinical Trials (4)

Showing 4 of 4 trials
NCT02992457Phase 4

Safety and Efficacy of Sofosbuvir-Based Regimens in the Treatment of Egyptian Patients With Hepatitis C Infection

Completed
NCT04353986Phase 3

PK of SOF/LED in HCV - Infected Adolescents With Haematological Disorders

Unknown
NCT04498936Phase 4

Sofosbuvir/Ledipasvir and Nitazoxanide for Treatment of COVID-19

Completed
NCT04047680

eGFR Evolution in HCV Patients Receiving SOF-based or SOF-free DAAs

Completed

All 4 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
4